JP2009523414A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009523414A5 JP2009523414A5 JP2008546448A JP2008546448A JP2009523414A5 JP 2009523414 A5 JP2009523414 A5 JP 2009523414A5 JP 2008546448 A JP2008546448 A JP 2008546448A JP 2008546448 A JP2008546448 A JP 2008546448A JP 2009523414 A5 JP2009523414 A5 JP 2009523414A5
- Authority
- JP
- Japan
- Prior art keywords
- dha
- epa
- lesion
- exercise
- oxidative damage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims description 12
- 230000003078 antioxidant effect Effects 0.000 claims description 3
- 239000002537 cosmetic Substances 0.000 claims description 3
- 235000016709 nutrition Nutrition 0.000 claims description 3
- 108091035539 telomere Proteins 0.000 claims description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims 20
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims 20
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims 20
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims 20
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims 20
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims 15
- 229940090949 docosahexaenoic acid Drugs 0.000 claims 10
- 230000004792 oxidative damage Effects 0.000 claims 9
- 235000013305 food Nutrition 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 230000007654 ischemic lesion Effects 0.000 claims 6
- 230000003902 lesion Effects 0.000 claims 6
- 208000013441 ocular lesion Diseases 0.000 claims 6
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 claims 5
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 claims 5
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 claims 5
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 208000002177 Cataract Diseases 0.000 claims 3
- 206010018364 Glomerulonephritis Diseases 0.000 claims 3
- 208000013016 Hypoglycemia Diseases 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 3
- 206010047115 Vasculitis Diseases 0.000 claims 3
- 230000032683 aging Effects 0.000 claims 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 3
- 206010003246 arthritis Diseases 0.000 claims 3
- 206010008118 cerebral infarction Diseases 0.000 claims 3
- 208000026106 cerebrovascular disease Diseases 0.000 claims 3
- 230000002218 hypoglycaemic effect Effects 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 206010025135 lupus erythematosus Diseases 0.000 claims 3
- 208000002780 macular degeneration Diseases 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 201000006938 muscular dystrophy Diseases 0.000 claims 3
- 208000010125 myocardial infarction Diseases 0.000 claims 3
- 230000004770 neurodegeneration Effects 0.000 claims 3
- 230000000626 neurodegenerative effect Effects 0.000 claims 3
- 230000008807 pathological lesion Effects 0.000 claims 3
- 230000004962 physiological condition Effects 0.000 claims 3
- 239000003642 reactive oxygen metabolite Substances 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 235000015872 dietary supplement Nutrition 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 claims 1
- 230000003712 anti-aging effect Effects 0.000 claims 1
- 235000013361 beverage Nutrition 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 235000013365 dairy product Nutrition 0.000 claims 1
- 235000005911 diet Nutrition 0.000 claims 1
- 230000000378 dietary effect Effects 0.000 claims 1
- 239000004744 fabric Substances 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 239000002088 nanocapsule Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 230000002028 premature Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000009758 senescence Effects 0.000 claims 1
- 238000004904 shortening Methods 0.000 claims 1
- 230000037384 skin absorption Effects 0.000 claims 1
- 231100000274 skin absorption Toxicity 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 238000011156 evaluation Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 210000003953 foreskin Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 238000010874 in vitro model Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200503202A ES2277557B1 (es) | 2005-12-21 | 2005-12-21 | Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo. |
| ES200602418A ES2315125B1 (es) | 2005-12-21 | 2006-09-25 | Mejoras en el objeto de la patente principal p 200503202, por "utilizacion de acido docosahexaenoico para el tratamiento del daño oxidativo celular". |
| ES200602417A ES2315124B1 (es) | 2005-12-21 | 2006-09-25 | Mejoras en el objeto de la patente principal p 200503202, por "utilizacion de acido docosahexaenoico para el tratamiento del daño oxidativo celular". |
| PCT/EP2006/070016 WO2007071733A2 (en) | 2005-12-21 | 2006-12-20 | Use of dha, epa or dha-derived epa for treating a pathology associated with cellular oxidative damage |
| ES200603231A ES2316263B1 (es) | 2005-12-21 | 2006-12-20 | Mejoras en el objeto de la patente principal p 200503202, por "utilizacion de acido docosahexaenoico para el tratamiento del daño oxidativo celular". |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013192263A Division JP2014028830A (ja) | 2005-12-21 | 2013-09-17 | 細胞の酸化的損傷に関連した病変を治療するためのｄｈａ、ｅｐａまたはｄｈａ由来のｅｐａの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009523414A JP2009523414A (ja) | 2009-06-25 |
| JP2009523414A5 true JP2009523414A5 (https=) | 2012-07-05 |
Family
ID=37728386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008546448A Pending JP2009523414A (ja) | 2005-12-21 | 2006-12-20 | 細胞の酸化的損傷に関連した病変を治療するためのｄｈａ、ｅｐａまたはｄｈａ由来のｅｐａの使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US9265745B2 (https=) |
| EP (3) | EP1962825B1 (https=) |
| JP (1) | JP2009523414A (https=) |
| KR (1) | KR101256448B1 (https=) |
| CN (1) | CN101346138B (https=) |
| AU (1) | AU2006327064B2 (https=) |
| BR (1) | BRPI0621131A2 (https=) |
| CA (1) | CA2632949C (https=) |
| ES (1) | ES2384701T3 (https=) |
| IL (1) | IL192154A (https=) |
| MX (1) | MX2008008171A (https=) |
| NO (1) | NO341240B1 (https=) |
| NZ (1) | NZ569676A (https=) |
| PL (1) | PL1962825T3 (https=) |
| RU (1) | RU2437583C2 (https=) |
| WO (1) | WO2007071733A2 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8252742B2 (en) * | 2004-12-30 | 2012-08-28 | Hill's Pet Nutrition, Inc. | Methods for enhancing the quality of life of a senior animal |
| ES2277557B1 (es) | 2005-12-21 | 2008-07-01 | Proyecto Empresarial Brudy, S.L. | Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo. |
| EP1962825B1 (en) | 2005-12-21 | 2014-04-02 | Brudy Technology, S.L. | Use of dha for treating a pathology associated with cellular oxidative damage |
| US20100119600A1 (en) | 2007-06-01 | 2010-05-13 | Joar Opheim | Substances for reducing occurrence of major cardiac events comprising red yeast rice extract and omega-3 polyunsaturated fatty acid or derivative thereof |
| US8343753B2 (en) | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
| US8207363B2 (en) | 2009-03-19 | 2012-06-26 | Martek Biosciences Corporation | Thraustochytrids, fatty acid compositions, and methods of making and uses thereof |
| CA2756528A1 (en) * | 2009-04-17 | 2010-10-21 | Celavista Pharmaceuticals Limited | Compositions rich in omega-3 fatty acids with a low content in phytanic acid |
| US9924733B2 (en) | 2010-01-19 | 2018-03-27 | Dsm Ip Assets B.V. | Eicosapentaenoic acid-producing microorganisms, fatty acid compositions, and methods of making and uses thereof |
| US20120252888A1 (en) * | 2011-03-29 | 2012-10-04 | Palupa Medical Ltd. | Compositions and Methods for Treating Neurologic Disorders |
| US20160310456A1 (en) * | 2013-03-12 | 2016-10-27 | Physicians Recommended Nutriceuticals, Llc | Compositions and methods for using same for reducing levels of arachidonic acid in tissue having undergone an invasive procedure |
| US10709680B2 (en) * | 2011-07-18 | 2020-07-14 | Physicians Recommended Nutriceuticals, Llc | Methods for treating dry eye |
| AU2012285806B2 (en) | 2011-07-21 | 2017-09-14 | Dsm Ip Assets B.V. | Fatty acid compositions |
| USRE48077E1 (en) | 2013-02-28 | 2020-07-07 | Anida Pharma Inc. | Methods of treating ototoxicity |
| CN103585140A (zh) * | 2013-11-22 | 2014-02-19 | 苏州麦可旺志生物技术有限公司 | Epa在制备溴酸钾诱导氧化应激性肾损伤药物中的应用 |
| EP3082405A4 (en) * | 2013-12-18 | 2017-12-13 | Commonwealth Scientific and Industrial Research Organisation | Lipid comprising long chain polyunsaturated fatty acids |
| US11718577B2 (en) | 2013-12-18 | 2023-08-08 | Commonwealth Scientific And Industrial Research Organisation | Lipid compositions comprising triacylglycerol with long-chain polyunsaturated fatty acids |
| EP3906920A1 (en) | 2014-06-06 | 2021-11-10 | Marine Ingredients, LLC | Omega-3 compositions, dosage forms, and methods of use |
| KR20180051737A (ko) * | 2016-11-08 | 2018-05-17 | 차의과학대학교 산학협력단 | 대장염-관련 암 발생을 줄이는 ω-3 폴리불포화지방산 활성 성분으로 포함하는 항암 조성물 |
| US20170156280A1 (en) | 2017-02-13 | 2017-06-08 | Bayer Cropscience Lp | Cotton variety st 5517gltp |
| US20170150690A1 (en) | 2017-02-13 | 2017-06-01 | Bayer Cropscience Lp | Cotton variety fm 1888gl |
| JP7133306B2 (ja) * | 2017-12-01 | 2022-09-08 | 国立大学法人九州大学 | アシルステリルグルコシド、アシルステリルグルコシドの製造方法、組成物、抗酸化剤、血中脂質低下剤、抗肥満剤、抗腫瘍剤及びアテローム性動脈硬化症の予防又は治療剤 |
| US12226390B2 (en) | 2019-07-21 | 2025-02-18 | Scf Pharma Inc. | Cannabinoids compositions with polyunsaturated fatty acid monoglycerides, methods and uses thereof |
| CN110846346B (zh) | 2019-11-26 | 2021-06-22 | 瞿瀚鹏 | 富含Sn-2位DHA的微生物油脂及其制备方法和应用 |
| AU2022322112A1 (en) * | 2021-08-04 | 2024-03-07 | Leiutis Pharmaceuticals Llp | Novel omega 3 carrier preparations for inhalation drug delivery for treating lung inflammation |
| CN113749255B (zh) * | 2021-09-15 | 2022-11-29 | 江南大学 | 一种磷脂组合物在修复肌肉损伤的应用 |
| WO2023122827A1 (en) * | 2021-12-28 | 2023-07-06 | Scf Pharma Inc. | Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof |
| CN116687902A (zh) * | 2023-06-14 | 2023-09-05 | 浙江大学 | Dha在制备促进心肌细胞增殖和心脏再生产品中的应用 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2524217B2 (ja) * | 1988-04-18 | 1996-08-14 | マルハ株式会社 | 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤 |
| GB2218984B (en) * | 1988-05-27 | 1992-09-23 | Renafield Limited | Process for preparing high-concentration mixtures of polyunsaturated fatty acids & their esters and their prophylactic or therapeutic uses |
| GB2223943A (en) | 1988-10-21 | 1990-04-25 | Tillotts Pharma Ag | Oral disage forms of omega-3 polyunsaturated acids |
| SE9101642D0 (sv) * | 1991-05-30 | 1991-05-30 | Kabi Pharmacia Ab | Phospholipids |
| CA2119000A1 (en) * | 1993-03-19 | 1994-09-20 | David Frederick Horrobin | Formulation for use in smokers |
| US20050027004A1 (en) * | 1993-06-09 | 2005-02-03 | Martek Biosciences Corporation | Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions |
| PT707487E (pt) * | 1993-06-09 | 2004-08-31 | Martek Biosciences Corp | Metodos e composicoes farmaceuticas uteis no tratamento de disturbios neurologicos |
| JPH07255417A (ja) * | 1994-03-25 | 1995-10-09 | Kanebo Ltd | 機能性健康食品 |
| FR2731015B1 (fr) * | 1995-02-24 | 1997-05-30 | Sci Sartone | Procede d'enrichissement enzymatique d'huiles d'origine marine et les triglycerides d'acides gras polyinsatures ainsi obtenus |
| US6582941B1 (en) * | 1995-04-17 | 2003-06-24 | Japan As Represented By Director-General Of Agency Of Industrial Science And Technology | Microorganisms capable of producing highly unsaturated fatty acids and process for producing highly unsaturated fatty acids by using the microorganisms |
| MY118354A (en) * | 1995-05-01 | 2004-10-30 | Scarista Ltd | 1,3-propane diol derivatives as bioactive compounds |
| JP3558423B2 (ja) * | 1995-09-11 | 2004-08-25 | 旭化成ケミカルズ株式会社 | ドコサヘキサエン酸を構成脂肪酸とするリン脂質の製造方法 |
| JP3985035B2 (ja) * | 1995-09-14 | 2007-10-03 | 独立行政法人産業技術総合研究所 | （ｎ−６）系ドコサペンタエン酸含有油脂ならびに該油脂の製造方法および用途 |
| WO1998028978A1 (en) * | 1996-05-08 | 1998-07-09 | Weider Nutrition Group, Inc. | Structured glycerols and structured phosphatides |
| US6509178B1 (en) * | 1996-07-23 | 2003-01-21 | Suntory Ltd. | Process for preparing docosahexaenoic acid and docosapentaenoic acid with ulkenia |
| US6313167B1 (en) | 1997-06-16 | 2001-11-06 | Nippon Suisan Kaisha Ltd. | Composition having capability of removing risk factor during exercise |
| JPH11239464A (ja) * | 1997-06-16 | 1999-09-07 | Nippon Suisan Kaisha Ltd | 運動時の危険因子除去能を有する組成物 |
| JPH11239465A (ja) * | 1997-06-16 | 1999-09-07 | Nippon Suisan Kaisha Ltd | 健常人が運動能力を高める食品 |
| GB9715444D0 (en) * | 1997-07-22 | 1997-09-24 | Scotia Holdings Plc | Therapeutic and dietary compositions |
| GB9901809D0 (en) | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
| IT1308613B1 (it) * | 1999-02-17 | 2002-01-09 | Pharmacia & Upjohn Spa | Acidi grassi essenziali nella prevenzione di eventi cardiovascolari. |
| JP2002040014A (ja) * | 2000-07-19 | 2002-02-06 | Nippon Steel Corp | 炭素含有耐火物の耐摩耗性、耐食性及び耐酸化性の評価方法 |
| EP1249523A1 (fr) * | 2001-04-12 | 2002-10-16 | Michel Beckers | Cylindre brouilleur et son utilisation |
| ITMI20020269A1 (it) * | 2002-02-12 | 2003-08-12 | Victorix Assets Ltd | Uso di steri etilici di acidi poliinsaturi omega-3 in pazienti con insufficienza cardiaca |
| AR039170A1 (es) | 2002-03-28 | 2005-02-09 | Bio Dar Ltd | Co-granulos de dha y romero y metodos de uso |
| US20040209953A1 (en) * | 2002-12-06 | 2004-10-21 | Wai Lee Theresa Siu-Ling | Glyceride compositions and methods of making and using same |
| US7041840B2 (en) * | 2002-12-18 | 2006-05-09 | Alberta Research Council Inc. | Antioxidant triacylglycerols and lipid compositions |
| JP2005000033A (ja) * | 2003-06-10 | 2005-01-06 | Shinbijuumu:Kk | 食品 |
| GB0314624D0 (en) * | 2003-06-23 | 2003-07-30 | Advanced Bionutrition Europ Lt | Inflammatory disease treatment |
| EP1660069A4 (en) | 2003-08-05 | 2009-03-18 | Univ Louisiana State | NEUROPROTECTION AGAINST CELL APOPTOSIS, NEURAL STROKES, ALZHEIMER DISEASE AND RETINAL DEGENERATION |
| JP2005068060A (ja) * | 2003-08-22 | 2005-03-17 | Nrl Pharma Inc | ラクトフェリンを含有する医薬組成物ならびに加工食品の製造法 |
| US20050130937A1 (en) * | 2003-10-22 | 2005-06-16 | Enzymotec Ltd. | Lipids containing omega-3 and omega-6 fatty acids |
| WO2005065669A1 (en) * | 2003-12-19 | 2005-07-21 | Alcon, Inc. | Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision |
| US20050163873A1 (en) | 2004-01-14 | 2005-07-28 | Robert Ritch | Methods and formulations for treating glaucoma |
| ITMI20040069A1 (it) | 2004-01-21 | 2004-04-21 | Tiberio Bruzzese | Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale |
| WO2006077495A1 (en) | 2005-01-24 | 2006-07-27 | Pronova Biocare As | Use of a fatty acid composition containing dha for the production of a medical product or a food stuff for the treatment of amyloidos-rerelated diseases |
| FR2882894B1 (fr) | 2005-03-11 | 2009-04-03 | Larena Sa | Composition alimentaire suppletive |
| ES2264886B1 (es) * | 2005-05-12 | 2008-02-01 | Proyecto Empresarial Brudy, S.L. | Utilizacion de acido docosahexaenoico para el tratamiento de enfermedades tumorales. |
| EP1962825B1 (en) | 2005-12-21 | 2014-04-02 | Brudy Technology, S.L. | Use of dha for treating a pathology associated with cellular oxidative damage |
-
2006
- 2006-12-20 EP EP06841516.5A patent/EP1962825B1/en active Active
- 2006-12-20 NZ NZ569676A patent/NZ569676A/en not_active IP Right Cessation
- 2006-12-20 KR KR1020087017876A patent/KR101256448B1/ko not_active Expired - Fee Related
- 2006-12-20 US US12/158,205 patent/US9265745B2/en active Active
- 2006-12-20 WO PCT/EP2006/070016 patent/WO2007071733A2/en not_active Ceased
- 2006-12-20 EP EP11189179.2A patent/EP2510927A3/en not_active Withdrawn
- 2006-12-20 JP JP2008546448A patent/JP2009523414A/ja active Pending
- 2006-12-20 MX MX2008008171A patent/MX2008008171A/es active IP Right Grant
- 2006-12-20 CN CN2006800488216A patent/CN101346138B/zh not_active Expired - Fee Related
- 2006-12-20 RU RU2008126805/13A patent/RU2437583C2/ru active
- 2006-12-20 CA CA2632949A patent/CA2632949C/en active Active
- 2006-12-20 ES ES06841516.5T patent/ES2384701T3/es active Active
- 2006-12-20 AU AU2006327064A patent/AU2006327064B2/en not_active Ceased
- 2006-12-20 BR BRPI0621131-3A patent/BRPI0621131A2/pt not_active Application Discontinuation
- 2006-12-20 PL PL06841516T patent/PL1962825T3/pl unknown
- 2006-12-20 EP EP17180553.4A patent/EP3263101A1/en not_active Withdrawn
-
2008
- 2008-06-12 IL IL192154A patent/IL192154A/en not_active IP Right Cessation
- 2008-07-17 NO NO20083187A patent/NO341240B1/no not_active IP Right Cessation
-
2013
- 2013-03-14 US US13/803,038 patent/US9259408B2/en active Active
-
2016
- 2016-02-08 US US15/017,877 patent/US20160151258A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009523414A5 (https=) | ||
| RU2437583C2 (ru) | Применение дгк (dha), эпк (epa) или эпк, полученных из дгк, для лечения патологии, связанной с окислительным повреждением клетки, a также их нетерапевтические применения | |
| JP6927660B2 (ja) | 皮膚外用組成物、及び経口組成物 | |
| TW201244637A (en) | Skin smoothing agent | |
| KR20240026947A (ko) | 살아있는 미생물의 캡슐화 | |
| KR20170067734A (ko) | 연캡슐 피막 | |
| JPWO2018199231A1 (ja) | プラセンタ抽出物 | |
| JP6281905B2 (ja) | 角栓形成抑制剤 | |
| JP5224770B2 (ja) | コラーゲン産生促進剤、促進方法、香粧品、飲食品および医薬品 | |
| JP2024074993A (ja) | 皮膚常在細菌叢改善又は多様化用剤及びそれを含有する組成物 | |
| KR20120119976A (ko) | 레독스 관련 인자 발현 촉진제 | |
| TW201111479A (en) | Antioxidant composition | |
| JP2005162663A (ja) | 皮膚用基剤 | |
| JP2003267857A (ja) | 皮膚外用剤及び皮膚外用剤組成物 | |
| JP6466125B2 (ja) | 経口組成物 | |
| JPH11240817A (ja) | 美容パック | |
| JP2011241188A (ja) | 表皮角化正常化剤、及び、該表皮角化正常化剤を含む皮膚外用剤、表皮正常化用外用剤、化粧料、表皮正常化用化粧料、医薬部外品、又は表皮正常化用医薬部外品 | |
| JP5024924B2 (ja) | 皮膚バリヤ機能改善剤 | |
| JP2004203812A (ja) | 経口組成物及びそれを有効成分とする美白剤 | |
| JP6522286B2 (ja) | ヒアルロン酸産生促進剤 | |
| TWI576117B (zh) | 玻尿酸產生促進劑 | |
| JP3706591B2 (ja) | 皮膚外用剤 | |
| JP2008208053A (ja) | 皮膚細胞増殖促進組成物およびその製造方法 | |
| KR102854836B1 (ko) | 어성초 캘러스 유래 엑소좀을 유효성분으로 포함하는 피부상태 개선용 조성물 | |
| JP2006001903A (ja) | 美白剤、及びそれを含有する組成物 |